Glenmark Pharmaceuticals Limited Stock price

Equities

GLENMARK

INE935A01035

Pharmaceuticals

Market Closed - NSE India S.E. 08:01:59 2024-03-28 am EDT 5-day change 1st Jan Change
958.4 INR -0.42% Intraday chart for Glenmark Pharmaceuticals Limited +1.82% +12.24%
Sales 2024 * 121B 1.45B Sales 2025 * 139B 1.67B Capitalization 272B 3.26B
Net income 2024 * 18.78B 225M Net income 2025 * 11.13B 133M EV / Sales 2024 * 2.4 x
Net Debt 2024 * 19.51B 234M Net cash position 2025 * 2.88B 34.56M EV / Sales 2025 * 1.93 x
P/E ratio 2024 *
39.9 x
P/E ratio 2025 *
23.8 x
Employees 15,556
Yield 2024 *
0.24%
Yield 2025 *
0.29%
Free-Float 49.03%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Glenmark Pharmaceuticals Limited

1 day-0.42%
1 week+1.24%
Current month+3.61%
1 month+5.19%
3 months+12.05%
6 months+23.36%
Current year+12.24%
More quotes
1 week
936.00
Extreme 936
969.40
1 month
883.00
Extreme 883
974.00
Current year
771.00
Extreme 771
974.00
1 year
444.30
Extreme 444.3
974.00
3 years
348.50
Extreme 348.5
974.00
5 years
161.65
Extreme 161.65
974.00
10 years
161.65
Extreme 161.65
1 262.90
More quotes
Managers TitleAgeSince
Founder - -
Chief Executive Officer 54 98-10-11
President - -
Members of the board TitleAgeSince
Director/Board Member 59 20-08-13
Director/Board Member 51 05-04-25
Director/Board Member 56 99-10-05
More insiders
Date Price Change Volume
24-03-28 958.4 -0.42% 517 943
24-03-27 962.4 +0.55% 752,945
24-03-26 957.2 +0.65% 685,483
24-03-22 951 +0.45% 792,841
24-03-21 946.7 +0.57% 721,888

Delayed Quote NSE India S.E., March 28, 2024 at 06:22 am EDT

More quotes
Glenmark Pharmaceuticals Limited is an India-based global pharmaceutical company. The Company is focused on building a global formulation business with branded, generics and over the counter (OTC) segments in the therapy areas of dermatology, respiratory and oncology. The Company also has a regional/country-specific presence in other therapeutic areas like diabetes, cardiovascular and oral contraceptives. Its product portfolio includes topical products, liquids, respiratory MDI/DPI, complex injectables and biologics, and oral solids. The Company has a bioequivalent version of Tiotropium Bromide dry powder inhaler (DPI) under the brand, Tiogiva in the United Kingdom and Tavulus in Spain, for the treatment of chronic obstructive pulmonary disease. Ryaltris, the Company's first branded specialty product globally, is a fixed dose combination nasal spray that combines an antihistamine (Olopatadine) with a steroid (Mometasone Furoate) for treatment of allergic rhinitis.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
962.4 INR
Average target price
923 INR
Spread / Average Target
-4.10%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Glenmark Pharmaceuticals Limited - NSE India S.E.